COMMUNIQUÉS West-GlobeNewswire

-
Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(C)(4)
12/04/2018 - 22:01 -
Munising Memorial Hospital Selects Cerner CommunityWorks℠
12/04/2018 - 22:01 -
Cytokinetics to Announce First Quarter Results on April 26, 2018
12/04/2018 - 22:00 -
Athersys to Host First Quarter Financial Results Call
12/04/2018 - 22:00 -
PCI Biotech: Exercise of employee share options and resolution to increase the share capital
12/04/2018 - 20:54 -
CORRECTION -- U.S. Undersecretary of Commerce and NIST Director Walter G. Copan Presents National Quality Award to Adventist Health
12/04/2018 - 19:09 -
Cynata to Present at the Preeminent Cell & Gene Therapy Investor Day in New York
12/04/2018 - 19:04 -
Resolution passed at the Annual General Meeting
12/04/2018 - 19:02 -
ContraVir Pharmaceuticals Announces New Data Presented at the 2018 International Liver Congress™
12/04/2018 - 18:46 -
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...
12/04/2018 - 18:16 -
Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financ...
12/04/2018 - 18:16 -
Terveystalo Plc: Resolutions of the Organizing Meeting of Board of Directors
12/04/2018 - 18:06 -
OSE Immunotherapeutics Announces Evolution in Company’s Board of Directors and Management
12/04/2018 - 18:00 -
Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at EASL 2018
12/04/2018 - 18:00 -
Virbac : 2018 first quarter revenue rose by +3.3% at comparable exchange rates
12/04/2018 - 17:46 -
Virbac : Chiffre d'affaires du premier trimestre 2018 en progression de +3,3% à taux de change comparables
12/04/2018 - 17:46 -
Nicox : Assemblées Générales Ordinaire et Extraordinaire 2018
12/04/2018 - 17:46 -
Clinical Cancer Research Publishes Phase I Data from a Study of Rafael Pharmaceuticals' Lead CPI-613 Compound in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia
12/04/2018 - 17:00 -
Terveystalo Plc: Resolutions of Annual General Meeting
12/04/2018 - 16:36
Pages